The analytical platform “Cursor” has presented a ranking of full-cycle manufacturers based on 2025 government procurement results. The ranking is grounded in data from documents issued by the Ministry of Industry and Trade of the Russian Federation, confirming production localization “down to the molecule.” Possessing such a document grants companies preferences when participating in tenders, as it certifies that critical stages—synthesis or cultivation—are carried out within the territory of the Eurasian Economic Union (EAEU).
According to the report, by the start of 2026, the Russian Ministry of Industry and Trade had confirmed full-cycle production for 169 INNs. Nearly 95% of these—159 items—are included in the list of Vital and Essential Drugs (VED), accounting for 18% of the entire list. Among the localized molecules, 106 are from chemical synthesis, and 63 are biotechnological and biological products.
The total volume of government procurement for drugs with confirmed full-cycle production in 2025 amounted to 116.9 billion rubles, a 22% decrease compared to 2024 (150.2 billion rubles). Analysts attribute this reduction to large-scale procurements in 2024, including vaccines under the national immunization schedule and eculizumab under the 14 High-Cost Nosologies program. The share of biotechnological drugs in monetary terms reached 86%, while chemical drugs accounted for only 14% of the total volume.
The undisputed leader in the ranking by sales volume was Biocad, with a result of 48.8 billion rubles, constituting 42% of the entire full-cycle drug market. The company holds 21 SP documents and showed positive dynamics of 3% relative to 2024. In second place was the R-Pharm group of companies (including R-Opra and Tekhnologiya Lekarstv) with a volume of 19.9 billion rubles and record growth of 89%. Third place was taken by Pharmstandard (with assets Generium and Dalionpharma)—16.4 billion rubles, although the company demonstrated a decline of 44%.
Top 10 Largest Full-Cycle Manufacturers in 2025:
| Company | Sales Volume, billion rubles |
|---|---|
| Biocad | 48.8 |
| R-Pharm | 19.9 |
| Pharmstandart | 16.4 |
| Geropharm | 7.7 |
| PharmFirma Sotex | 3.25 |
| Velfarm | 2.68 |
| Pharmapark | 2.39 |
| Advanced Pharma | 1.86 |
| Natsimbio | 1.48 |
| Medsintez Plant | 1.42 |
Meanwhile, Velfarm leads in the number of issued SP documents—the company produces 27 full-cycle INNs. The report confirms a sustained trend towards deepening production localization, particularly in the biotechnological drug segment, despite the overall reduction in procurement volume in 2025.
Since January 1, 2026, the “second one out” mechanism has come into force for strategically significant medicines produced via the full cycle. The new rules require manufacturers not only to register in the traceability system but also to provide detailed data on the origin and composition of the raw materials used.
